Could Cannabinoids Help Recovery After Open-Heart Surgery?

Preclinical evidence suggests CBD has anti-inflammatory, analgesic, and neuroprotective properties relevant to post-cardiac surgery recovery. The endocannabinoid system plays a role in managing physiological processes disrupted by cardiopulmonary bypass, and CBD has shown promise in managing ischemia/reperfusion injury in preclinical models.

Narrative review of preclinical evidence on cannabinoids in the context of open-heart surgery complications including pain, systemic inflammation, and organ damage.

Post-cardiac surgery pain management relies heavily on opioids, which carry addiction and side effect risks. If cannabinoids can reduce opioid requirements while addressing inflammation and tissue protection, this could significantly improve surgical recovery.

This represents a novel application area for cannabinoid therapeutics. The combination of anti-inflammatory, analgesic, and tissue-protective properties makes cannabinoids theoretically well-suited for post-surgical care, but the gap between preclinical promise and clinical reality remains large.

Entirely based on preclinical evidence. No clinical trials in cardiac surgery patients. Cannabinoid interactions with cardiac medications and anesthetics are poorly understood. Post-surgical patients are a complex, high-risk population for any new intervention.